Candel Therapeutics Inc (CADL)vsNovartis AG ADR (NVS)
CADL
Candel Therapeutics Inc
$6.18
-0.32%
HEALTHCARE · Cap: $476.11M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 182509574% more annual revenue ($56.58B vs $31,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CADL
Avoid20
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CADL.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CADL
CADL has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CADL
The primary concerns for CADL are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
CADL profiles as a value stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
CADL is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 20/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Candel Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Candel Therapeutics Inc. is an innovative biotechnology firm specializing in oncolytic virus technology to create localized therapies that effectively target cancerous cells while safeguarding healthy tissue. Focused on boosting anti-tumor immunity, Candel's robust pipeline offers solutions for a range of challenging malignancies, reflecting its commitment to overcoming treatment obstacles in oncology. Backed by a comprehensive intellectual property portfolio and strategic collaborations with prominent research institutions, Candel is well-positioned to lead transformative developments in cancer care, ultimately enhancing patient outcomes and advancing the field of oncology.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?